抗真菌薬に対する多剤耐性を克服する
1Department of Oral Sciences, Faculty of Dentistry, University of Otago, Post Office Box 647, Dunedin, New Zealand.
Science (New York, N.Y.)
|July 19, 2008
まとめ
多剤耐性菌感染症は,高価で致命的です. 新しい広範な殺菌剤は,流出ポンプとその遺伝子発現を標的にし,耐性に対抗する多機能的なアプローチを提供することができる.
科学分野:
- ミコロジー菌類学
- 薬用化学 薬用化学について
- 分子生物学は分子生物学である.
背景:
- 多剤耐性による真菌感染症による高い経済的負担と死亡率.
- プラズマ膜流出ポンプの転写制御に関する新たな理解.
研究 の 目的:
- 菌類の多剤耐性を標的とする新しい広範囲の真菌殺菌剤を探求する.
- 多機能アゾールアナログを開発し,治療効果を組み合わせる.
主な方法:
- 流出ポンプの転写制御を調査する.
- エルゴステロールのバイオシンセシスとエフフルスポンプの活性を抑制するアゾール類の設計.
- 流出ポンプ発現のための転写機構の阻害を調査する.
主要な成果:
- 排気ポンプの調節を,抗真菌薬の開発の実行可能なターゲットとして特定する.
- エルゴステロール合成とエフフルスポンプに対する二重作用の多機能アゾールアナログの構想.
- 薬物の流出ポンプの転写的活性化を阻害する可能性がある.
結論:
- 多機能アゾールアナログは,真菌の多剤耐性を克服するための有望な戦略を提供します.
- エルゴステロールのバイオシンセシスとエフフルスポンプメカニズムの両方をターゲットにすることで,抗真菌効果を高めることができます.
- 流出ポンプの転写制御を阻害することは,新しい治療の道を示しています.
関連する概念動画
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...